Drugs / Sapylin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05131711 | Nov 2021 → Nov 2022 | glioblastoma | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07327216 | Aug 2022 → Jul 2026 overdue | nasopharyngeal carcinoma | Affiliated Hospital of Guangdong Medical University | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02158299 | Oct 2013 → Nov 2014 | — | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sapylin | “stereotactic radiosurgery and GM-CSF, Sapylin, MnCl2” NCT05131711 ↗ |
| Known as | OK-432 | “Microfibrillar Collagen Hemostat Flour（Avitene） And OK-432 （Sapylin）in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer” NCT02158299 ↗ |
| Modality | Other / unclassified | “Sapylin, a biological immune regulator” NCT07327216 ↗ |
| Route | Other | “Atomized inhalation, 1 KE/time, QD from day 1 of CCRT until the end of radiotherapy.” NCT07327216 ↗ |